Surgical excision margins for primary cutaneous melanoma. 2009

Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
Department of Medicine, University of Tasmania, Launceston General Hospital, Launceston, Tasmania, Australia, 7250.

BACKGROUND Cutaneous melanoma accounts for 75% of skin cancer deaths. Standard treatment is surgical excision with a safety margin some distance from the borders of the primary tumour. The purpose of the safety margin is to remove both the complete primary tumour and any melanoma cells that might have spread into the surrounding skin.Excision margins are important because there could be trade-off between a better cosmetic result but poorer long-term survival if margins become too narrow. The optimal width of excision margins remains unclear. This uncertainty warrants systematic review. OBJECTIVE To assess the effects of different excision margins for primary cutaneous melanoma. METHODS In August 2009 we searched for relevant randomised trials in the Cochrane Skin Group Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 3, 2009), MEDLINE, EMBASE, LILACS, and other databases including Ongoing Trials Registers. METHODS We considered all randomised controlled trials (RCTs) of surgical excision of melanoma comparing different width excision margins. METHODS We assessed trial quality, and extracted and analysed data on survival and recurrence. We collected adverse effects information from included trials. RESULTS We identified five trials. There were 1633 participants in the narrow excision margin group and 1664 in the wide excision margin group. Narrow margin definition ranged from 1 to 2 cm; wide margins ranged from 3 to 5 cm. Median follow-up ranged from 5 to 16 years. CONCLUSIONS This systematic review summarises the evidence regarding width of excision margins for primary cutaneous melanoma. None of the five published trials, nor our meta-analysis, showed a statistically significant difference in overall survival between narrow or wide excision.The summary estimate for overall survival favoured wide excision by a small degree [Hazard Ratio 1.04; 95% confidence interval 0.95 to 1.15; P = 0.40], but the result was not significantly different. This result is compatible with both a 5% relative reduction in overall mortality favouring narrower excision and a 15% relative reduction in overall mortality favouring wider excision. Therefore, a small (but potentially important) difference in overall survival between wide and narrow excision margins cannot be confidently ruled out.The summary estimate for recurrence free survival favoured wide excision [Hazard Ratio 1.13; P = 0.06; 95% confidence interval 0.99 to 1.28] but again the result did not reach statistical significance (P < 0.05 level).Current randomised trial evidence is insufficient to address optimal excision margins for primary cutaneous melanoma.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
September 1997, Journal of the American Academy of Dermatology,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
April 2011, Clinical and experimental dermatology,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
January 2004, Clinics in dermatology,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
June 1993, The British journal of surgery,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
July 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
April 2011, Cutis,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
August 1992, Journal of the American Academy of Dermatology,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
January 2016, Cancer treatment reviews,
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
November 2019, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Michael J Sladden, and Charles Balch, and David A Barzilai, and Daniel Berg, and Anatoli Freiman, and Teenah Handiside, and Sally Hollis, and Marko B Lens, and John F Thompson
March 2014, Journal of plastic, reconstructive & aesthetic surgery : JPRAS,
Copied contents to your clipboard!